Berlin's GCS Closes €10M Cannabis Investment Round
German Cannabis Standard (GCS) co-founders Dr. Nikolaos Katsaras and Dogan Küncekli. © Markus Braumann
Berlin-based cannabis technology company GCS (German Cannabis Standard) has successfully closed a €10 million funding round, marking what the company claims is Europe's largest cannabis investment in 2025. The round values the startup at €60 million and signals growing confidence in Germany's evolving medical cannabis market.
According to information from Startbase, a significant portion of the investment comes from a German family office, which is also providing approximately 21,000 square meters of production space in Solar Valley Bitterfeld-Wolfen, Saxony-Anhalt. Construction has already begun on what will become one of Germany's three largest GMP-compliant medical cannabis production facilities.
"We didn't start as first movers, but we want to set standards as best movers. This financing turns our vision into our mission," said Dogan Küncekli, co-founder of GCS.
GCS operates a vertically integrated ecosystem spanning research, cultivation, digital platforms, and pharmacy supply chains.
The new Bitterfeld-Wolfen facility will be built to GMP standards and certified by Germany's Federal Institute for Drugs and Medical Devices (BfArM).
GCS Technology encompasses multiple digital platforms. Blütezeit Health provides patients with digital access to medical cannabis through telehealth consultations and e-prescriptions sent directly to pharmacies. Cannaflow serves as B2B infrastructure, digitalizing ordering processes between pharmacies, wholesalers, and telemedicine providers. Cannabiosan operates as a pharmacy purchasing cooperative, offering better conditions through bundled demand, particularly benefiting smaller rural locations.
"Cannaflow is becoming the industry's digital hub. Blütezeit Health also demonstrates that telehealth can be legally compliant and user-friendly," explained Henrik Willen, co-founder of Cannaflow and Blütezeit Health.
The German medical cannabis market has expanded significantly since the Medical Cannabis Act (MedCanG) took effect in April 2024, removing cannabis from narcotics legislation and introducing e-prescriptions as standard practice while eliminating cultivation quotas.
